COPDwear: A Wearable and a Self-management Application for Chronic Obstructive Pulmonary Disease (COPD) Patients at Home

Sponsor
University Health Network, Toronto (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03857061
Collaborator
University of Toronto (Other), Samsung Electronics (Industry)
30
1
30.1
1

Study Details

Study Description

Brief Summary

Our overall research goal for this project is to create a wearable device and mobile application, appealing to patients with Chronic Obstructive Pulmonary Disease (COPD), which provides them with appropriate self-management tools and detects AECOPDs early to permit prompt treatment and prevent severe exacerbations requiring hospitalization.

Condition or Disease Intervention/Treatment Phase
  • Device: smartphone, smartwatch, WearCOPDv2 application

Detailed Description

Our overall research goal for this project is to create a wearable device and mobile application, appealing to patients with COPD, which provides them with appropriate self-management tools and detects Acute Exacerbations of COPD (AECOPDs) early to permit prompt treatment and prevent severe exacerbations requiring hospitalization. Currently, the investigators are developing a second version of this app, WearCOPDv2. This app will incorporate features identified as being desirable from our patient interviews: 1) new sensor that was requested by patients - oxygen saturation, and 2) the app will incorporate a patient-facing interface as patients requested a method to view their data as well as access to information to learn how to manage their condition better.

Research questions:

Can an app designed for patients with COPD that includes biosensor feedback improve self-management of COPD?

What is the accuracy of our sensor data (heart rate, activity, respiratory rate, oxygen saturation, coughing, and other sounds of interest) in detecting early AECOPDs?

Study Design

Study Type:
Observational
Actual Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
COPDwear V2 - A Wearable and a Self-management Application for COPD Patients at Home: a Pilot Prospective Cohort Study
Actual Study Start Date :
Jun 29, 2019
Actual Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
COPD Patients

This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.

Device: smartphone, smartwatch, WearCOPDv2 application
WearCOPD2 consists of hardware and software components. 6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server. 6.2 Software The wearCOPDv2 system has two main software components: Data collection service Participant user interface

Outcome Measures

Primary Outcome Measures

  1. Change in self-management as measured by the Mastery sub-section of the Chronic Respiratory Disease Questionnaire [6 months]

    Can an app designed for patients with COPD that includes biosensor feedback improve self-management of COPD? We will use the Mastery sub-section of the Chronic Respiratory Disease Questionnaire to measure our research question. Mastery is measured with a 7-point likert scale where higher scores indicate better health-related mastery.

Secondary Outcome Measures

  1. Change in self-efficacy as measured by the COPD Self-Efficacy Scale [6 months]

    Can an app designed for patients with COPD that includes biosensor feedback improve self-efficacy of COPD? This will be measured by the COPD self-efficacy scale. Participants will determine how confident they are that they could manage breathing difficulty or avoid breathing difficulty in certain situations. Usin the following scale. Very confident Pretty confident Somewhat confident Not very confident Not at all confident A lower score indicates higher self-efficacy.

  2. Change in Health related quality of life as measured by the St. George's respiratory questionnaire [6 months]

    Can an app designed for patients with COPD that includes biosensor feedback improve health related quality of life? Scoring and Scales Questions 1 - 7 Scale: Most days a week - Not At All Where a patient has ticked a box, a value of 1 is entered for the appropriate question. Question 8 Where a patient has ticked 'Yes' to having a worse wheeze in the morning, a value of 1 is entered for the appropriate question. Questions 9, 10 & 17 Where a patient has ticked a box, a value of 1 is entered for the appropriate question. Questions 11 - 16 Where a patient has ticked 'True' a value of 1 is entered for the appropriate question. In response to question 14, if a patient is not receiving medication, enter the responses as zero. Score = 100 x (Summed weights from positive items in the questionnaire divided by the Sum of weights for all items in the questionnaire) lower scores indicate higher health related quality of life

  3. Change in symptom scale as measured by the MRC dyspnea scale [6 months]

    Can an app designed for patients with COPD that includes biosensor feedback improve COPD symptoms? The MRC Dyspnea scale asks you to rate your breathlessness on a 5 point likert scale.

  4. Accuracy of our derived prediction algorithm to detect acute exacerbations as measured by the daily symptom score. [6 months]

    We will correlate sensor data from the smartwatch to exacerbations defined by the daily symptom score. The daily symptom score asks about daily symptoms of COPD and patients are asked to answer yes or no to whether or not they have experienced a decline of any of the symptoms

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Able to speak English

  • Moderate to very severe COPD (GOLD C and D) as defined by the GOLD guidelines

  • Clinically relevant disease, as defined by a history of exacerbation in the previous 12 months

  • Previous spirometry or Pulmonary Function Test results of Forced Expiration Volume/Forced Vital Capacity (FEV1/FVC) <0.70 with an FEV1 below 80% predicted

  • Patient resides at home (not long term care residence or another hospital)

Exclusion Criteria:
  • Pulmonary condition other than COPD as the main respiratory disease such as bronchiectasis or asthma

  • Rapid lethal disease, e.g. lung cancer, advance heart failure, end-stage renal disease

  • Any medical conditions that would impair their ability to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toronto General Hospital Toronto Ontario Canada M5G 2C4

Sponsors and Collaborators

  • University Health Network, Toronto
  • University of Toronto
  • Samsung Electronics

Investigators

  • Principal Investigator: Robert Wu, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Robert Wu, General Internal Medicine Site Director, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT03857061
Other Study ID Numbers:
  • 18-5462
First Posted:
Feb 27, 2019
Last Update Posted:
Sep 8, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Robert Wu, General Internal Medicine Site Director, University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 8, 2021